表紙
市場調查報告書

裘馨氏肌肉萎縮症:開發平台分析

Duchenne Muscular Dystrophy - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 232813
出版日期 內容資訊 英文 330 Pages
訂單完成後即時交付
價格
Back to Top
裘馨氏肌肉萎縮症:開發平台分析 Duchenne Muscular Dystrophy - Pipeline Review, H2 2019
出版日期: 2019年11月25日內容資訊: 英文 330 Pages
簡介

裘馨氏肌肉萎縮症 是引起肌肉無力,鏈接到X染色體的疾病。有這個疾病的遺傳基因在X染色體中,編碼於Dystrophin蛋白。 Dystrophin是在肌肉細胞內支撐組織結構不可或缺的物質。症狀通常在 6歲左右或比其年幼時出現,可觀察到疲勞、學習障礙、知的障礙、肌肉無力、進行性步行困難。

本報告提供裘馨氏肌肉萎縮症的治療藥開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關最新的開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等新聞和發表。

簡介

  • 調查範圍

裘馨氏肌肉萎縮症 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

企業開發中的產品

大學/機關研究中的產品

開發治療藥的企業

  • Acceleron Pharma, Inc.
  • Anagenesis Biotechnology
  • Asklepios BioPharmaceutical, Inc.
  • Bamboo Therapeutics, Inc.
  • BioMarin Pharmaceutical Inc.
  • Bristol-Myers Squibb Company
  • Capricor Therapeutics, Inc.
  • Catabasis Pharmaceuticals, Inc.
  • 第一三共
  • Debiopharm International S.A.
  • Editas Medicine, Inc.
  • Eli Lilly and Company
  • EryDel SPA
  • FibroGen, Inc.
  • Galapagos NV
  • Genethon
  • GTx, Inc.
  • Idera Pharmaceuticals, Inc.
  • Italfarmaco S.p.A.
  • La Jolla Pharmaceutical Company
  • Marathon Pharmaceuticals, LLC
  • Marina Biotech, Inc.
  • Merck KGaA
  • Milo Biotechnology LLC
  • MyoTherix Inc.
  • NicOx S.A.
  • 日本新藥
  • nLife Therapeutics, S.L.
  • Nobelpharma Co., Ltd.
  • Pfizer Inc.
  • Prothelia, Inc.
  • PTC Therapeutics, Inc.
  • RASRx, LLC
  • ReveraGen BioPharma, Inc.
  • Sanofi
  • Santhera Pharmaceuticals Holding AG
  • Sarepta Therapeutics, Inc.
  • Summit Therapeutics Plc
  • 大鵬藥品工業
  • WAVE Life Sciences Ltd.
  • Zambon Company S.p.A.

治療藥的評估

  • 單劑產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • 4-P001
  • AAV1-Foliistatin
  • ACE-083
  • alisporivir
  • 裘馨氏肌肉萎縮症用Dystrophin活性反義寡核苷酸 1
  • 裘馨氏肌肉萎縮症用Dystrophin活性反義寡核苷酸
  • 裘馨氏型/貝克氏肌肉萎縮症用肌肉生長抑制素抑制反義寡核苷酸
  • 裘馨氏肌肉萎縮症用 ACVR2B抑制反義寡核苷酸
  • 裘馨氏肌肉萎縮症用反義RNAi寡核苷酸
  • 遺傳性疾病、肌肉骨骼障礙用Calcineurin活性核酸適體
  • arbekacin
  • ARM-210
  • AT-300
  • ataluren
  • Biostrophin
  • BMBD-001
  • BMN-044
  • BMN-045
  • BMN-053
  • BMS-986089
  • CAP-1002
  • CAT-1004
  • CAT-1040
  • CAT-1041
  • DA-4210
  • deflazacort
  • dexamethasone sodium phosphate
  • domagrozumab
  • drisapersen
  • 裘馨氏肌肉萎縮症治療藥
  • DS-5141b
  • DT-200
  • enobosarm
  • eteplirsen
  • FG-3019
  • 裘馨氏肌肉萎縮症用遺傳基因療法
  • 裘馨氏型/肢帶型肌萎縮症用Dysferlin活性遺傳基因療法
  • 裘馨氏肌肉萎縮症用Dystrophin活性遺傳基因療法
  • givinostat
  • Gtx-027
  • IB-DMD
  • idebenone
  • IMO-8400
  • LJPC-30Sa
  • LJPC-30Sb
  • MG-53
  • MP-101
  • Myomir
  • naproxcinod
  • NBD Peptide
  • NS-065
  • 裘馨氏肌肉萎縮症用Dystrophin活性寡核苷酸
  • 裘馨氏肌肉萎縮症用Dystrophin活性寡核苷酸 1
  • 裘馨氏肌肉萎縮症用Dystrophin活性寡核苷酸 2
  • 裘馨氏肌肉萎縮症用Dystrophin活性寡核苷酸 3
  • 缺血性心臟疾病、裘馨氏肌肉萎縮症用寡核苷酸
  • OSX-200
  • poloxamer
  • PRO-052
  • PRO-055
  • PRT-01
  • 肌肉萎縮症用組換蛋白質
  • 肌肉萎縮症用Utrophin活性組換蛋白質
  • 裘馨氏肌肉萎縮症用組換蛋白質
  • rimeporide
  • RTC-13
  • 裘馨氏肌肉萎縮症用小分子
  • 裘馨氏肌肉萎縮症用Dystrophin活性小分子
  • 裘馨氏肌肉萎縮症用小分子
  • 裘馨氏肌肉萎縮症用Utrophin標靶藥物
  • SMT-022357
  • SMTC-1100
  • SRP-4008
  • SRP-4044
  • SRP-4045
  • SRP-4050
  • SRP-4052
  • SRP-4053
  • SRP-4055
  • 裘馨氏肌肉萎縮症用Dystrophin活性幹細胞療法
  • Stryka-516
  • Stryka-969
  • StrykaPro-1
  • 裘馨氏肌肉萎縮症用合成肽
  • tadalafil
  • TAS-205
  • TVN-102
  • TXA-127
  • Verolone
  • ZP-049
  • ■最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11566IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Duchenne Muscular Dystrophy - Pipeline Review, H2 2019, provides an overview of the Duchenne Muscular Dystrophy (Genetic Disorders) pipeline landscape.

Duchenne muscular dystrophy (DMD) is a genetic disorder that causes muscles to gradually weaken over time. Signs and symptoms of DMD include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking. Risk factors include gender and family history. Treatment includes steroid medication, respiratory therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Duchenne Muscular Dystrophy - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Duchenne Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 3, 4, 13, 8, 1, 51, 24 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 1, 10 and 2 molecules, respectively.

Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Duchenne Muscular Dystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Duchenne Muscular Dystrophy - Overview
  • Duchenne Muscular Dystrophy - Therapeutics Development
  • Duchenne Muscular Dystrophy - Therapeutics Assessment
  • Duchenne Muscular Dystrophy - Companies Involved in Therapeutics Development
  • Duchenne Muscular Dystrophy - Drug Profiles
  • Duchenne Muscular Dystrophy - Dormant Projects
  • Duchenne Muscular Dystrophy - Discontinued Products
  • Duchenne Muscular Dystrophy - Product Development Milestones
  • Appendix

List of Tables

  • Table 1: Number of Products under Development for Duchenne Muscular Dystrophy, H2 2019
  • Table 2: Number of Products under Development by Companies, H2 2019
  • Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Table 5: Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Table 6: Number of Products under Development by Universities/Institutes, H2 2019
  • Table 7: Products under Development by Companies, H2 2019
  • Table 8: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Table 9: Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Table 10: Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Table 11: Products under Development by Companies, H2 2019 (Contd..4), H2 2019
  • Table 12: Products under Development by Companies, H2 2019 (Contd..5), H2 2019
  • Table 13: Products under Development by Companies, H2 2019 (Contd..6), H2 2019
  • Table 14: Products under Development by Universities/Institutes, H2 2019
  • Table 15: Number of Products by Stage and Target, H2 2019
  • Table 16: Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
  • Table 17: Number of Products by Stage and Mechanism of Action, H2 2019
  • Table 18: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
  • Table 19: Number of Products by Stage and Route of Administration, H2 2019
  • Table 20: Number of Products by Stage and Molecule Type, H2 2019
  • Table 21: Duchenne Muscular Dystrophy - Pipeline by 4D Molecular Therapeutics Inc, H2 2019
  • Table 22: Duchenne Muscular Dystrophy - Pipeline by Advanced Medical Projects, H2 2019
  • Table 23: Duchenne Muscular Dystrophy - Pipeline by Akashi Therapeutics Inc, H2 2019
  • Table 24: Duchenne Muscular Dystrophy - Pipeline by Alpha Anomeric, H2 2019
  • Table 25: Duchenne Muscular Dystrophy - Pipeline by Anagenesis Biotechnologies SAS, H2 2019
  • Table 26: Duchenne Muscular Dystrophy - Pipeline by Antisense Therapeutics Ltd, H2 2019
  • Table 27: Duchenne Muscular Dystrophy - Pipeline by Armgo Pharma Inc, H2 2019
  • Table 28: Duchenne Muscular Dystrophy - Pipeline by Audentes Therapeutics Inc, H2 2019
  • Table 29: Duchenne Muscular Dystrophy - Pipeline by AUM LifeTech Inc, H2 2019
  • Table 30: Duchenne Muscular Dystrophy - Pipeline by Avidity Biosciences LLC, H2 2019
  • Table 31: Duchenne Muscular Dystrophy - Pipeline by Axolo Pharma Inc, H2 2019
  • Table 32: Duchenne Muscular Dystrophy - Pipeline by Beech Tree Labs Inc, H2 2019
  • Table 33: Duchenne Muscular Dystrophy - Pipeline by Biogen Inc, H2 2019
  • Table 34: Duchenne Muscular Dystrophy - Pipeline by Bioleaders Corp, H2 2019
  • Table 35: Duchenne Muscular Dystrophy - Pipeline by Biophytis SA, H2 2019
  • Table 36: Duchenne Muscular Dystrophy - Pipeline by Capricor Therapeutics Inc, H2 2019
  • Table 37: Duchenne Muscular Dystrophy - Pipeline by Cardero Therapeutics Inc, H2 2019
  • Table 38: Duchenne Muscular Dystrophy - Pipeline by Catabasis Pharmaceuticals Inc, H2 2019
  • Table 39: Duchenne Muscular Dystrophy - Pipeline by Consortium.AI, H2 2019
  • Table 40: Duchenne Muscular Dystrophy - Pipeline by Constant Therapeutics LLC, H2 2019
  • Table 41: Duchenne Muscular Dystrophy - Pipeline by CRISPR Therapeutics AG, H2 2019
  • Table 42: Duchenne Muscular Dystrophy - Pipeline by Cumberland Pharmaceuticals Inc, H2 2019
  • Table 43: Duchenne Muscular Dystrophy - Pipeline by Daiichi Sankyo Co Ltd, H2 2019
  • Table 44: Duchenne Muscular Dystrophy - Pipeline by DepYmed Inc, H2 2019
  • Table 45: Duchenne Muscular Dystrophy - Pipeline by DMD Therapeutics Inc, H2 2019
  • Table 46: Duchenne Muscular Dystrophy - Pipeline by Dyne Therapeutics Inc, H2 2019
  • Table 47: Duchenne Muscular Dystrophy - Pipeline by Dystrogen Therapeutics SA, H2 2019
  • Table 48: Duchenne Muscular Dystrophy - Pipeline by Edgewise Therapeutics, H2 2019
  • Table 49: Duchenne Muscular Dystrophy - Pipeline by Editas Medicine Inc, H2 2019
  • Table 50: Duchenne Muscular Dystrophy - Pipeline by Eloxx Pharmaceuticals Inc, H2 2019
  • Table 51: Duchenne Muscular Dystrophy - Pipeline by Evox Therapeutics Ltd, H2 2019
  • Table 52: Duchenne Muscular Dystrophy - Pipeline by FibroGen Inc, H2 2019
  • Table 53: Duchenne Muscular Dystrophy - Pipeline by Fulcrum Therapeutics Inc, H2 2019
  • Table 54: Duchenne Muscular Dystrophy - Pipeline by Galapagos NV, H2 2019
  • Table 55: Duchenne Muscular Dystrophy - Pipeline by Hibernaid Inc, H2 2019
  • Table 56: Duchenne Muscular Dystrophy - Pipeline by InnoBioscience LLC, H2 2019
  • Table 57: Duchenne Muscular Dystrophy - Pipeline by Italfarmaco SpA, H2 2019
  • Table 58: Duchenne Muscular Dystrophy - Pipeline by Keros Therapeutics Inc, H2 2019
  • Table 59: Duchenne Muscular Dystrophy - Pipeline by LambdaGen Therapeutics, H2 2019
  • Table 60: Duchenne Muscular Dystrophy - Pipeline by Milo Biotechnology LLC, H2 2019

List of Figures

  • Figure 1: Number of Products under Development for Duchenne Muscular Dystrophy, H2 2019
  • Figure 2: Number of Products under Development by Companies, H2 2019
  • Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
  • Figure 4: Number of Products by Targets, H2 2019
  • Figure 5: Number of Products by Stage and Targets, H2 2019
  • Figure 6: Number of Products by Mechanism of Actions, H2 2019
  • Figure 7: Number of Products by Stage and Mechanism of Actions, H2 2019
  • Figure 8: Number of Products by Routes of Administration, H2 2019
  • Figure 9: Number of Products by Stage and Routes of Administration, H2 2019
  • Figure 10: Number of Products by Top 10 Molecule Types, H2 2019
  • Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019
Back to Top